Patent intelligence · US
US 11583542
Compositions of bile acids and phenylbutyrate compounds
Compositions of bile acids and phenylbutyrate compounds
Patent details — US 11583542
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 21, 2023
- Expiration
- Feb 16, 2043
- Applicant
- Amylyx Pharmaceuticals, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/192, A61K31/216, A61K31/575
Quick answer
US 11583542 (Compositions of bile acids and phenylbutyrate compounds) is held by Amylyx Pharmaceuticals, Inc.. Status: granted. Granted Feb 21, 2023. Expires Feb 16, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Amylyx Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/192, A61K31/216, A61K31/575, A61K47/02, A61K47/26
More from Amylyx Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12246027
Compositions of bile acids and phenylbutyrate compounds
granted -
US 12186330
Compositions for improving cell viability and methods of use thereof
granted -
US 12138272
Methods and compositions for treating amyotrophic lateral sclerosis
granted -
US 11559533
Compositions of bile acids and phenylbutyrate compounds
granted -
US 11071742
Compositions for improving cell viability and methods of use thereof
granted -
US 10857162
Compositions for improving cell viability and methods of use thereof
granted -
US 10251896
Compositions for improving cell viability and methods of use thereof
granted
Frequently asked questions
What is US patent 11583542?
US 11583542 (Compositions of bile acids and phenylbutyrate compounds) is held by Amylyx Pharmaceuticals, Inc.. Status: granted. Granted Feb 21, 2023. Expires Feb 16, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11583542?
Amylyx Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 11583542 expire?
Our index shows an expiration date of Feb 16, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.